Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Université De Technologie De Compiègne

Chiesi Farmaceutici S.p.a.

Johan Hoebeke

Bernard P Roques

Guido Kroemer

Etienne Daniel Francois Jacotot

Lena Edelman

Catherine Brenner-Jean

Anne-Sophie Belzacq

Gilles Guichard

Michel Langlois

Arthur Donny Strosberg

Rodolphe Fischmeister

David Chauvier

Richard Casimir

Jean G Guillet

Sylvie Victorine Lucienne Fournel

Olivier Blondel

Yamina Dahmoune

Monique Gastineau

Olivier Chaloin

Cuong Tram

Nathalie Trouche

Sêbastien Wieckowski

A compound of formula (I) is described, wherein Y represents a macrocycle, the ring of which has 9 to 36 atoms, and is functionalized by three amine or COOH functions; Rrepresents a group of formula H&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;(X)&#x2014;, i represents 0 or 1, Xis in particular lysine, arginine, or ornithine residues, Xis in particular glycine, asparagine, L-proline or D-proline residues, Xand Xare in particular tyrosine, phenylalanine or 3-nitrotyrosine residues, Xand Xare in particular amino acid residues: NH&#x2014;(CH)&#x2014;COOH, n ranging from 1 to 10, or NH&#x2014;(CH&#x2014;CH&#x2014;O)&#x2014;CHCHCOOH, m ranging from 3 to 6, provided that at least one of the amino acid residues X, X, Xand Xis different from the corresponding amino acid in the sequence of the natural CD40Lys-Gly-Tyr-Tyrfragment(SEQ ID NO: 1).

Multimeric CD40 ligands, method for preparing same and use thereof for preparing drugs

The present disclosure relates to peptides having a core sequence as described herein as well as application of the disclosed technology as inhibitors of caspase-2 and/or -6 activity.

Peptides useful as dual caspase-2/-6 inhibitors and their biological applications

The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.

Screening methods for the identification of inhibitors of human immunodeficiency virus (HIV) viral protein R (Vpr) binding to the adenine nucleotide translocator (ANT)

Mimetics and inhibitors of the interaction between Vpr (HIV viral protein of regulation) and ANT (Mitochondrial adenine nucleotide translocator)

The invention concerns an isolated polypeptide constitutive of splice variants for human serotonin receptor whereof the amino acid sequence is selected among the sequence SEQ ID No. 2 of the 5-HT polypeptide variant or the sequence SEQ ID No. 4 of the 5-HT polypeptide variant, or any polypeptide fragment or biologically active derivative thereof. The invention also concerns the inverse agonist effect of ML 10375 on 5-HT4(c) and 5-HT4(d) receptors.

Splice variants for human 5-HT4 serotonin receptor and their applications, in particular for screening

A process to produce hybrid cell lines, which produce monoclonal antibodies to Legionella pneumophila. Cell lines are produced by fusion of immunized mouse splenocytes to these bacteria with non secreting myeloma cells. Monoclonal antibodies are useful for diagnosis of diseases due to Legionella pneumophilia, for detection of these bacteria in environment, for the production of vaccines.

Monoclonal antibodies to legionella, a process for their preparation and

Growing community of inventors

Schiltigheim, France

Johan Hoebeke